Founded in 1992, Cubist has maintained its focus on becoming a leader in the discovery, development and commercialization of novel anti-infectives for use in hospitals and other acute-care environments. CUBICIN® (daptomycin for injection), our first in class I.V. antibiotic, has experienced the most successful I.V. antibiotic launch, in dollar terms, in U.S. history. Cubist continues to move forward confidently and successfully as an acute care focused therapeutics company, committed to improving patients' lives, while maintaining a clear-eyed focus on growing long-term shareholder value, and nurturing an innovative culture for its employees.
Crucial to the success of any organization is its people, and Cubist is blessed with an abundance of talent at every level of the company. Good people attract other good people and that was further validated in 2008 when Cubist was named to The Boston Globe 100 Top Places to Work '08. In addition, on May 19, 2009, Cubist was ranked first among the "Top 100" Massachusetts-based publicly traded companies by The Boston Globe in its 21st annual "Globe 100" listing. Cubist is only the third life sciences company in Massachusetts to appear at the top of the Globe 100 rankings, and as a company that researches, develops, and brings to market pharmaceutical products, the first of its kind to achieve this distinction. The Northeastern University Co-op Program at Cubist provides students with the opportunity to experience this culture as they gain real-world industry experience.
Joseph Terracciano, Senior Manager of the Cubist Fermentation Pilot Plant, has been involved with the Northeastern Co-op Program for several years and says, "We have hired Co-op students to work in the Pilot Plant, where they have the opportunity to learn about bacterial fermentation and work in a state-of-the-art facility. During Co-op, students interact with the entire fermentation group and learn how to set up and operate fermenters that range in size from 5-to-100 liters, equipment not readily available in most academic settings." Current plans call for expanding the Co-op program into other areas of the organization.
Having Co-op students for an entire six-month period has been invaluable for Joe's team. "Due to the nature of the position, there is a one-to-two month learning curve and because we have the student for six months, there is adequate time for training as well as for students being able to make positive contributions to the group. The Co-op student becomes a member of the team, working on group as well as individual projects, and not just another pair of hands."
Joe also says "All of the Co-op students who have worked at Cubist impress me with their dedication and genuine interest in science. I hope that some of these students will make Cubist a career choice after graduation."
About Cubist Pharmaceuticals
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute-care environment. In the U.S., Cubist markets CUBICIN®(daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist entered into an agreement with AstraZeneca to promote their established antibiotic, MERREM® I.V. (meropenem for injection), in the United States. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials - CONSERVTM-1 and CONSERVTM-2 - for the reduction of blood loss during on pump cardiac surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam (Cambridge, MA), has a pre-IND and a Phase 2 program underway for novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist is headquartered in Lexington, Mass. Additional information may be found at Cubist Pharmaceuticals.